← All candidates
86 insider filings on record.
86 filings on record.
STOKStoke Therapeutics, Inc.
NasdaqGS · Healthcare · $1.80B
$27.91
-0.85% · Sep 16
86 insider filings on record.
None of them an open-market buy in the last year.
Price · 1Y · daily● 51 sells
▸ hover a marker for the filing · drag to zoom · daily bars sharpen to 30-min on close ranges · 4 moves explained
AI brief · from the filings on this pagePro
The filings, the score and the setup on this page, read for you in about ten seconds — what the insiders did, and what stands against it.
Market cap
$1.80B
Float
49.2M
76% public
Short % float
Pro
Price / profit
—
not yet profitable
Price / future profit
—
Price / sales
65.3
Institutional stakes
▸ a holder crossing 5% files Schedule 13D if they intend to act on the company, 13G if they certify they will not · /A amends an earlier filing
2 filingsnewest first
The record
newest first
DateTypeInsiderOf stakeShares @ priceValue
81 more transactions on Pro →Context
Wall St
$45.10 avg target
+61.6% vs today · 10 analysts · consensus Strong Buy
▸ relayed analyst opinion, which tends to run optimistic — not our forecast or advice
Earnings · EPS vs forecast
2 of 4 quarters beat
Q1 '26−$0.79 act+$0.03
Q4 '25−$0.97 act−$0.23
Q3 '25−$0.65 act−$0.08
Q2 '25−$0.40 act+$0.14
Coverage
Stoke Therapeutics (STOK) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?Zacks · 06-04Stoke Therapeutics, Inc. (STOK) Reports Q1 Results and Business UpdatesInsider Monkey · 06-01Stoke Therapeutics, Inc. (NASDAQ:STOK) Analysts Are Pretty Bullish On The Stock After Recent ResultsSimply Wall St. · 05-11Stoke Therapeutics Q1 Earnings Call HighlightsMarketBeat · 05-09
The file stays open
86 filings on record.
The next one will be too.
▸ SEC EDGAR · FINRA · Nasdaq — public sources only · research, not advice